Evidence map›Paper›PMID 31754833›Full record

ArticleJournal of cancer research and clinical oncology2020

High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1.

Yukio Maezawa, Kentaro Sakamaki, Naohide Oue, Yayoi Kimura, Itaru Hashimoto, Kentaro Hara, Kazuki Kano, Toru Aoyama, Yukihiko Hiroshima, Takanobu Yamada and 12 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Plasma proteomic signatures improve risk stratification and personalized screening for gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 2 countries.

Yukio MaezawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Kentaro SakamakiDepartment of Biostatistics Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8658, Japan.
Naohide OueDepartment of Molecular Pathology, Hiroshima University Institute of Biomedical and Health Science, Hiroshima, 734-8551, Japan.
Yayoi KimuraAdvanced Medical Research Center, Yokohama City University, Yokohama, Kanagawa, 236-0004, Japan.
Itaru HashimotoDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Kentaro HaraDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Kazuki KanoDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Toru AoyamaDepartment of Surgery, Yokohama City University, Yokohama, Kanagawa, 236-0004, Japan.
Yukihiko HiroshimaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Takanobu YamadaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Naoto YamamotoDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Takashi OgataDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Hiroyuki ItoDepartment of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Haruhiko ChoDepartment of Surgery, Yokohama City University, Yokohama, Kanagawa, 236-0004, Japan.
Manabu ShiozawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Takaki YoshikawaDepartment of Surgery, Yokohama City University, Yokohama, Kanagawa, 236-0004, Japan.
Soichiro MorinagaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University, Yokohama, Kanagawa, 236-0004, Japan.
Wataru YasuiDepartment of Molecular Pathology, Hiroshima University Institute of Biomedical and Health Science, Hiroshima, 734-8551, Japan.
Munetaka MasudaDepartment of Surgery, Yokohama City University, Yokohama, Kanagawa, 236-0004, Japan.
Yohei MiyagiKanagawa Cancer Center Research Institute, Yokohama, Kanagawa, 241-8515, Japan.
Takashi OshimaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan. oshimat@kcch.jp.ORCID http://orcid.org/0000-0003-3349-2649
Kanagawa Prefectural Hospital Organization · JPYokohama City University · JPHiroshima University · JPNational Cancer Center · USThe University of Tokyo · JPTokyo Metropolitan Komagome Hospital · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe enzymes gamma-glutamyl hydrolase (GGH) and folylpolyglutamate synthetase (FPGS) regulate intracellular folate concentrations needed for cell proliferation, DNA synthesis, and repair. High GGH expression affects 5-FU thymidylate synthase (TS) inhibition and is a risk factor for various malignancies. Here, the clinical significance of GGH and FPGS expression was investigated in Stage II/III gastric cancer patients undergoing postoperative adjuvant chemotherapy with S-1.

methodsSurgical specimens of cancer tissue and adjacent normal mucosa, obtained from 253 patients with previously untreated gastric cancer, were examined. GGH and FPGS mRNA expression was measured by qPCR to evaluate their clinicopathological significance in gastric cancer patients after curative resection.

resultsWhile FPGS expression showed no significant differences between the cancerous and normal samples, GGH expression was higher in cancer tissue than in adjacent normal mucosa. High GGH expression was correlated with age, histological type, and vascular invasion. Overall survival (OS) of patients with high GGH mRNA expression was significantly poorer than of patients with low GGH expression. Multivariate analysis showed that high GGH expression was an independent prognostic factor of OS (HR: 2.58, 95% CI 1.29-5.16). Patients who received S-1 adjuvant treatment showed a significantly poor OS between high GGH/low FPGS and low GGH/high FPGS. Patients without adjuvant treatment showed no significant difference.

conclusionGGH expression was significantly higher in gastric cancer tissue than in adjacent normal mucosa. High GGH and low FPGS expression is a useful independent predictor of poor outcomes in stage II/III gastric cancer patients undergoing postoperative adjuvant chemotherapy with S-1.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChemotherapy, AdjuvantDrug CombinationsFemalegamma-Glutamyl HydrolaseGastric MucosaGene ExpressionHumansMaleMiddle AgedNeoplasm StagingOxonic AcidBiomarkers, TumorDrug Combinationsfolylpolyglutamate synthetasegamma-Glutamyl HydrolaseOxonic AcidPeptide SynthasesRNA, MessengerS 1 (combination)TegafurFolylpolyglutamate synthetase (FPGS)Gamma-glutamyl hydrolase (GGH)Gastric cancerPrognostic factorS-1

Identifiers

PMID31754833
PMCPMC6942012
OpenAlexW2991639845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.